Armatus Bio

Armatus Bio is a precision pharmaceutical company focused on developing innovative therapeutics through genetic science and bioengineering. The firm specializes in vectorized RNA interference (RNAi) therapeutics, utilizing technology licensed from Nationwide Children's Hospital. Their approach targets autosomal dominant neurological diseases and employs compartmentalized dosing strategies to enhance systemic delivery for conditions such as facioscapulohumeral muscular dystrophy (FSHD). By leveraging advanced engineering methodologies, Armatus Bio aims to drive disruptive innovations that transition precision treatments from the research phase to mainstream clinical care, ultimately improving the effectiveness and efficiency of life-saving drugs. The company also seeks partnerships to further develop and expand its therapeutic assets.